Research programme: G protein-coupled receptor modulators - Amgen/Daiichi Sankyo
Latest Information Update: 12 May 2008
Price :
$50 *
At a glance
- Originator Amgen; Daiichi Sankyo Company
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Metabolic disorders
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 08 Mar 2004 Tularik and Sankyo have expanded their collaboration to jointly discover and develop human therapeutics that act on GPCRs